公开(公告)号：US09993540B2

公开(公告)日：2018-06-12

申请号：US15638806

申请日：2017-06-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K35/17 ,  A61K39/00

CPC classification number: C07K7/06 ,  A61K35/17 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55588 ,  A61K2039/572 ,  A61K2039/605 ,  A61K2039/6081 ,  A61K2039/6093 ,  A61M5/002 ,  C07K7/08 ,  C07K14/70539 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0638 ,  C12N2501/50 ,  G01N33/57492 ,  Y02A50/472

Abstract: A method of treating a patient who has brain cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has brain cancer. A method of treating a patient who has brain cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the brain cancer.

公开(公告)号：US20170326217A1

公开(公告)日：2017-11-16

申请号：US15638806

申请日：2017-06-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K39/00

CPC classification number: C07K7/06 ,  A61K35/17 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55588 ,  A61K2039/572 ,  A61K2039/605 ,  A61K2039/6081 ,  A61K2039/6093 ,  A61M5/002 ,  C07K7/08 ,  C07K14/70539 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0638 ,  C12N2501/50 ,  G01N33/57492 ,  Y02A50/472

Abstract: A method of treating a patient who has brain cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has brain cancer. A method of treating a patient who has brain cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the brain cancer.

公开(公告)号：US11607446B2

公开(公告)日：2023-03-21

申请号：US17165638

申请日：2021-02-02

Applicant: Immatics Biotechnologies GmbH

Inventor： Sabrina Kuttruff-Coqui ,  Toni Weinschenk ,  Jens Fritsche ,  Steffen Walter ,  Norbert Hilf ,  Oliver Schoor ,  Colette Song ,  Harpreet Singh

IPC: A61K39/00 ,  A61K38/17 ,  C07K14/47 ,  C07K14/705 ,  A61K35/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/74 ,  C07K16/28 ,  C12Q1/6886

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US11524059B2

公开(公告)日：2022-12-13

申请号：US17852205

申请日：2022-06-28

Applicant: Immatics Biotechnologies GmbH

Inventor： Sabrina Kuttruff-Coqui ,  Toni Weinschenk ,  Jens Fritsche ,  Steffen Walter ,  Norbert Hilf ,  Oliver Schoor ,  Colette Song ,  Harpreet Singh

IPC: C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  A61P35/02 ,  A61P35/00 ,  A61K35/17 ,  A61K39/00 ,  C12N5/0783 ,  C07K14/705 ,  C07K7/06 ,  C07K7/08 ,  C12Q1/6886

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US11136352B2

公开(公告)日：2021-10-05

申请号：US17238840

申请日：2021-04-23

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K35/17 ,  C07K7/06 ,  A61K39/00 ,  C07K7/08 ,  G01N33/574 ,  C07K14/74 ,  A61M5/00 ,  C12N5/0783 ,  A61K38/00

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US20210238227A1

公开(公告)日：2021-08-05

申请号：US17238806

申请日：2021-04-23

Applicant: Immatics Biotechnologies GMBH

Inventor： Toni WEINSCHENK ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: C07K7/06 ,  A61K39/00 ,  C07K7/08 ,  A61K35/17 ,  G01N33/574 ,  C07K14/74 ,  A61M5/00 ,  C12N5/0783

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US12221493B2

公开(公告)日：2025-02-11

申请号：US17238806

申请日：2021-04-23

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K38/00 ,  A61K35/17 ,  A61K39/00 ,  A61M5/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/74 ,  C12N5/0783 ,  C12N5/0784 ,  G01N33/574 ,  C07K7/00

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US11529400B1

公开(公告)日：2022-12-20

申请号：US17852206

申请日：2022-06-28

Applicant: Immatics Biotechnologies GmbH

Inventor： Sabrina Kuttruff-Coqui ,  Toni Weinschenk ,  Jens Fritsche ,  Steffen Walter ,  Norbert Hilf ,  Oliver Schoor ,  Colette Song ,  Harpreet Singh

IPC: C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  A61P35/02 ,  A61P35/00 ,  A61K35/17 ,  A61K39/00 ,  C12N5/0783 ,  C07K14/705 ,  C07K7/06 ,  C07K7/08 ,  C12Q1/6886

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US10946064B2

公开(公告)日：2021-03-16

申请号：US14531472

申请日：2014-11-03

Applicant: immatics biotechnologies GmbH

Inventor： Sabrina Kuttruff-Coqui ,  Toni Weinschenk ,  Jens Fritsche ,  Steffen Walter ,  Norbert Hilf ,  Oliver Schoor ,  Colette Song ,  Harpreet Singh

IPC: A61K39/00 ,  A61K38/17 ,  C07K14/47 ,  C07K14/705 ,  A61K35/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/74 ,  C07K16/28 ,  C12Q1/6886

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US10919931B2

公开(公告)日：2021-02-16

申请号：US15226126

申请日：2016-08-02

Applicant: immatics biotechnologies GmbH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K38/00 ,  C07K7/06 ,  A61K39/00 ,  C07K7/08 ,  A61K35/17 ,  G01N33/574 ,  C07K14/74 ,  A61M5/00 ,  C12N5/0783

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.